Callan JMB（CJMB）株式概要Callan JMB Inc.は子会社のColdchain Technology Services, LLCを通じて、米国のライフサイエンス業界に熱管理物流ソリューションを提供している。 詳細CJMB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間115.9%減少しました。 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $11M )過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見るCJMB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW468,491 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA468,491 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$2.191.6k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m20m2016201920222025202620282031Revenue US$5.4mEarnings US$226.3kAdvancedSet Fair ValueView all narrativesCallan JMB Inc. 競合他社VerifyMeSymbol: NasdaqCM:VRMEMarket cap: US$9.4mCellyan BiotechnologySymbol: NasdaqCM:HKPDMarket cap: US$9.7mJayud Global LogisticsSymbol: NasdaqCM:JYDMarket cap: US$7.5mCheetah Net Supply Chain ServiceSymbol: NasdaqCM:CTNTMarket cap: US$5.1m価格と性能株価の高値、安値、推移の概要Callan JMB過去の株価現在の株価US$2.1952週高値US$5.6152週安値US$0.65ベータ01ヶ月の変化188.46%3ヶ月変化119.09%1年変化-53.89%3年間の変化n/a5年間の変化n/aIPOからの変化-46.59%最新ニュースNew Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 116% per year over the past 5 years. Market cap is less than US$10m (US$4.86m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).お知らせ • Jul 04Callan Jmb Inc Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementOn June 29, 2026, Callan JMB Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer satisfies the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 28, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period, although Nasdaq may, in its discretion, require the Company to maintain a closing bid price of at least $1.00 per share for a period in excess of ten consecutive business days (generally no more than 20 consecutive business days) before determining that the Company has regained compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by December 28, 2026, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the applicable compliance period(s), Nasdaq will provide notice that the Company’s common stock will be subject to delisting, at which time the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, which may include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or will otherwise maintain compliance with the other listing requirements of The Nasdaq Capital Market.お知らせ • Jun 12Callan Jmb Inc. Announces Resignation of Eric Kash from Executive Vice President and Board Member Roles, Effective June 5, 2026Callan JMB Inc. announced that on June 5, 2026, Eric Kash resigned from his position as Executive Vice President of Callan JMB Inc., and from his position as a member of the Board of Directors of the Company, including any committee positions, effective as of June 5, 2026. Mr. Kash's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.お知らせ • May 28Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • May 18First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.32 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.32 loss in 1Q 2025). Revenue: US$1.11m (down 24% from 1Q 2025). Net loss: US$3.22m (loss widened 159% from 1Q 2025).お知らせ • Apr 12Callan JMB Inc. Receives Nasdaq Notice of Non-Compliance with Stockholders' Equity RequirementOn April 7, 2026 Callan JMB Inc. (the Company) received a deficiency letter (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market (the Stockholders' Equity Requirement). In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 22, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement. Subsequent to the receipt of the Notice, and prior to that deadline, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement to Nasdaq. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq may, in its discretion, grant the Company up to 180 calendar days from the date of the Notice, or until October 4, 2026, to evidence compliance. Neither the Notice nor the Company's non-compliance have an immediate effect on the listing or trading of the Company's common stock, which will continue to trade under the symbol CJMB. However, these can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance.最新情報をもっと見るRecent updatesNew Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 116% per year over the past 5 years. Market cap is less than US$10m (US$4.86m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).お知らせ • Jul 04Callan Jmb Inc Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementOn June 29, 2026, Callan JMB Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer satisfies the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 28, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period, although Nasdaq may, in its discretion, require the Company to maintain a closing bid price of at least $1.00 per share for a period in excess of ten consecutive business days (generally no more than 20 consecutive business days) before determining that the Company has regained compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by December 28, 2026, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the applicable compliance period(s), Nasdaq will provide notice that the Company’s common stock will be subject to delisting, at which time the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, which may include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or will otherwise maintain compliance with the other listing requirements of The Nasdaq Capital Market.お知らせ • Jun 12Callan Jmb Inc. Announces Resignation of Eric Kash from Executive Vice President and Board Member Roles, Effective June 5, 2026Callan JMB Inc. announced that on June 5, 2026, Eric Kash resigned from his position as Executive Vice President of Callan JMB Inc., and from his position as a member of the Board of Directors of the Company, including any committee positions, effective as of June 5, 2026. Mr. Kash's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.お知らせ • May 28Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • May 18First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.32 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.32 loss in 1Q 2025). Revenue: US$1.11m (down 24% from 1Q 2025). Net loss: US$3.22m (loss widened 159% from 1Q 2025).お知らせ • Apr 12Callan JMB Inc. Receives Nasdaq Notice of Non-Compliance with Stockholders' Equity RequirementOn April 7, 2026 Callan JMB Inc. (the Company) received a deficiency letter (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market (the Stockholders' Equity Requirement). In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 22, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement. Subsequent to the receipt of the Notice, and prior to that deadline, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement to Nasdaq. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq may, in its discretion, grant the Company up to 180 calendar days from the date of the Notice, or until October 4, 2026, to evidence compliance. Neither the Notice nor the Company's non-compliance have an immediate effect on the listing or trading of the Company's common stock, which will continue to trade under the symbol CJMB. However, these can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance.New Risk • Apr 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (82% average weekly change). Revenue has declined by 13% over the past year. Market cap is less than US$10m (US$7.37m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Reported Earnings • Apr 04Full year 2025 earnings released: US$1.82 loss per share (vs US$0.87 loss in FY 2024)Full year 2025 results: US$1.82 loss per share (further deteriorated from US$0.87 loss in FY 2024). Revenue: US$5.72m (down 13% from FY 2024). Net loss: US$7.97m (loss widened 247% from FY 2024).お知らせ • Mar 11Callan Jmb Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’S Ind Clinical Trials for Lodonal™ in the Treatment of Long CovidCallan JMB Inc. announced that it has agreed with Biostax Corp. d/b/a Attune Biotech Inc. to support its investigational new drug clinical trials for the treatment of Post-Acute Sequelae of SARS-CoV-2 infection (“PASC”), commonly known as Long COVID. The Company previously announced in January 2026, that it had signed a strategic teaming agreement with Attune, whereby Callan JMB serves as independent third-party overseer of Attune's manufacturing, quality assurance and control, and deployment operations. Under this agreement, Callan JMB will provide the following services and oversight for IND 181314 for JKB-122 (lodonal™), including Contract Manufacturing Organization (CMO) qualification and validation, comprehensive batch record review, supply chain verification and integrity confirmation, surge manufacturing capacity assessment, and distribution pathway validation. Attune has received notification that the U.S. Food and Drug Administration (FDA) has received and assigned Investigational New Drug (IND) application number 181314 for JKB-122 (lodonal™) for treatment of Long COVID, which remains a condition for which no FDA-approved therapies are currently indicated. Patients of Long COVID are currently underserved, with approximately 20 million Americans estimated to be living with Long COVID or persistent post-COVID symptoms. In addition, the U.S. Department of Health and Human Services (HHS) has issued formal guidance titled “Long COVID as a Disability Under the ADA, Section 504, and Section 1557” (last reviewed July 2025), confirming that Long COVID may qualify as a disability under federal civil rights statutes where symptoms substantially limit major life activities. lodonal™ (JKB-122) is a first-in-class TLR4 antagonist for immune restoration, currently in development across five parallel clinical programs including Long COVID, HIV immune non-responders, autoimmune hepatitis, metabolic liver diseases (MASLD/MASH), and chronic immune pain. Under IND 181314, Attune intends to initiate a randomized, double-blind, placebo-controlled, multi-center Phase 2b/3 clinical trial evaluating the safety, tolerability, and efficacy of JKB-122 (lodonal™) in adults diagnosed with PASC or Long COVID. The product remains investigational and has not been approved by the U.S. Food and Drug Administration. JKB-122 is protected by issued intellectual property extending through 2041.New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 81% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (81% average weekly change). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$5.18m market cap).お知らせ • Dec 07Callan JMB Inc. Appoints Christopher Shields as Interim Chief Financial Officer, Effective December 1, 2025Callan JMB Inc. appointed Christopher Shields, the Company’s Senior Vice President (Governmental Affairs), to serve as Interim Chief Financial Officer until a permanent Chief Financial Officer is appointed, effective December 1, 2025. Mr. Shields, age 57, has served as the Company’s Senior Vice President (Governmental Affairs), since April 15, 2025, pursuant to the employment agreement, dated March 15, 2025. Prior to joining the Company, Mr. Shields served as Assistant Commissioner (Bureau of Preparedness and Response) with Chicago Department of Public Health, City of Chicago, from February 2011 to March 2025, where he led City of Chicago’s efforts to prepare for and respond to the health consequences of disasters including severe weather, special events, infectious diseases, chemical/biological/radiological releases. Additionally, Mr. Shields has more than three decades of experience managing operations and logistics components of various stages and branches of public health emergency preparedness and response, among others. Mr. Shields received a B.S., in Community Health Administration in 1990 from Northern Illinois University, DeKalb, Illinois, and also completed the Critical Infrastructure Protection Certificate Program at the Texas A&M Engineering Extension Service (TEEX) between 2016 to 2017. Mr. Shields currently serves on Northern Illinois University’s College of Health and Human Sciences Advisory Board.New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Dec 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap).お知らせ • Dec 01Callan JMB Inc., Annual General Meeting, Dec 29, 2025Callan JMB Inc., Annual General Meeting, Dec 29, 2025.Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.61 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.61 loss per share (further deteriorated from US$0.27 loss in 3Q 2024). Revenue: US$1.45m (flat on 3Q 2024). Net loss: US$2.73m (loss widened 239% from 3Q 2024).お知らせ • Nov 11Callan JMB Inc. Expands Logistics Platform into Food Sampling Sector, Advancing Multi-Variant Growth StrategyCallan JMB Inc. announced the expansion of its reclamation operations into the food sampling industry. This move is part of Callan JMB's multi-variant strategic growth initiative designed to extend its proven compliance-driven model into adjacent, high-growth markets. Building on a long history of excellence in pharmaceutical and regulated material logistics, Callan JMB is applying its expertise in product integrity, recall readiness, and traceability to support the specialized needs of food brands and distributors managing large-scale sampling programs. While most food sampling programs focus on reach and trial, few have standardized sustainable packaging or waste-reduction practices -- creating an accountability gap. As brands face increasing pressure to cut waste and measure impact, the sampling channel presents a clear opportunity for logistics partners that deliver sustainability, compliance, and traceability. The expansion was made possible through Callan JMB's relationship with Keychain, an AI-powered platform for the consumer packaged goods (CPG) industry. Supporting over $1 billion in monthly manufacturing projects, Keychain's platform connects 30,000 manufacturers with 20,000 brands and retailers, helping them bring new products to market faster, more responsibly, and with greater precision. While specific forecasts for food sampling services are limited, the broader food logistics market--valued at over $120 billion globally and growing at a rate of 6-10% annually-- offers a strong platform for expansion. Callan JMB's entry into this fast-emerging segment supports brands responding to the growing demand for sustainable, compliant sampling and distribution. With the U.S. specialty food sector projected to reach $130 billion by 2032 (Data Bridge Market Research, 2024), this expansion reinforces Callan JMB's commitment to diversification, sustainability, and cross-sector resilience.お知らせ • Oct 14Callan Jmb Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature MonitoringCallan JMB INC. announced that it has upgraded its proprietary Sentry Monitoring System technology with version 4.0 for temperature-sensitive storage to significantly increase flexibility and accessibility for its customers. The Sentry Monitoring System is a platform that allows remote monitoring of refrigerators, freezers, and clean room temperatures for high-value pharmaceutical products in pharmacies, hospitals, and emergency preparedness facilities. The upgraded version, Sentry 4.0, provides the user with the same 24/7/365 active monitoring by Callan JMB staff, alarm notifications, and compliant reporting data that are currently available with the Sentry 3 system, but with improved accessibility for users on the go. Sentry 4.0 allows users to access a consistent interface across all systems and devices - PC or Mac, an iPhone or Android, or any tablet. This flexibility enables the customer to address environmental anomalies in their pharmaceutical storage units from any available device, without having to download additional programs. With Sentry 4.0, Callan JMB has raised the bar for secure, reliable, and easy-to-use temperature monitoring that is critical to the medical and pharmaceutical industries. The upgraded system is now available to new and existing customers.Reported Earnings • Aug 15Second quarter 2025 earnings released: US$0.31 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.31 loss per share (further deteriorated from US$0.015 loss in 2Q 2024). Revenue: US$1.67m (down 16% from 2Q 2024). Net loss: US$1.40m (loss widened US$1.28m from 2Q 2024).お知らせ • Jul 26Callan JMB Inc. announced that it expects to receive $25 million in fundingCallan JMB Inc. announced it has entered into a Purchase Agreement with a certain investor (ELOC agreement) whereby the Company has the right, but not the obligation, to sell to the Investor, up to an aggregate of $25,000,000 of shares (the “ ELOC Shares ”) of the Company’s common stock, par value $0.001 per share, subject to the terms and conditions on July 24, 2025. The term of the Purchase Agreement is through the first day of the month immediately following the eighteen (18) month anniversary of the Commencement Date or the date on which the Investor has purchased ELOC Shares pursuant to the Purchase Agreement for an aggregate purchase price of the Investment Amount. The Company has also agreed to issue to the Investor 15,000 shares of Common Stock (the “ Commitment Shares ”), to be issued to the Investor upon the effectiveness of the registration statement registering the resale of the ELOC Shares and the Commitment Shares. The issuance of the shares of ELOC Shares to the Investor is being made pursuant to exemptions from the registration requirement of the Securities Act of 1933, as amended (the “ Securities Act ”) provided by Section 4(a)(2) of the Securities Act.分析記事 • Jul 17Companies Like Callan JMB (NASDAQ:CJMB) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • May 16First quarter 2025 earnings released: US$0.32 loss per share (vs US$0.032 loss in 1Q 2024)First quarter 2025 results: US$0.32 loss per share (further deteriorated from US$0.032 loss in 1Q 2024). Revenue: US$1.45m (down 19% from 1Q 2024). Net loss: US$1.24m (loss widened US$1.16m from 1Q 2024).お知らせ • Apr 25Callan JMB Inc. Appoints Christopher Shields, as Senior Vice President of Emergency Preparedness & Response/Government AffairsCallan JMB INC. announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Mr. Shields is an industry veteran with decades of experience managing complex public safety responses to a diverse array of crises both domestically and internationally. Most recently, Mr. Shields served for over 14 years as Assistant Commissioner at the Chicago Department of Public Health, where he oversaw operations and logistics for the city’s Emergency Preparedness and Bioterrorism program. His responsibilities included managing day-to-day operations of the Tier 1 Medical Pharmacy, overseeing advanced vaccine inventory and storage systems, and leading critical functions such as the Continuity of Operations group, Emergency Operations Planning team, and Tactical Communications platform. Mr. Shields has held various leadership positions responsible for humanitarian aid/disaster relief (HADR) and emergency responses to health impacts including September 11, 2001, Hurricane Katrina 2005, H1N1 Pandemic 2009-2010, NATO 2012, Ebola 2014-2016, Hurricane Maria, SARSCoV-2 Pandemic 2020-2023, Operation Allies welcome, Monkey Pox MPV outbreak 2022, humanitarian migration response from South America (2022 - ongoing), Ebola (Sudan virus) 2022-2023, Measles 2024, the Democratic National Convention (DNC) 2024 and the Rwanda Marburg operation/ORD 2024.Recent Insider Transactions • Apr 04Chief Medical Officer recently bought US$113k worth of stockOn the 27th of March, David Croyle bought around 25k shares on-market at roughly US$4.50 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$253k. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months.Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive VP & Director Eric Kash is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 30Full year 2024 earnings released: US$0.87 loss per share (vs US$0.44 profit in FY 2023)Full year 2024 results: US$0.87 loss per share (down from US$0.44 profit in FY 2023). Revenue: US$6.56m (down 50% from FY 2023). Net loss: US$2.29m (down 205% from profit in FY 2023).お知らせ • Feb 28Callan Jmb Inc. Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private OrganizationsCallan JMB INC. announced a new comprehensive lease program for vaccine management that will enable government agencies and private organizations to provide crucial immunizations without the economic burden of purchasing the necessary equipment outright. Under this program, Callan JMB can not only assist agencies in developing their plans, but can lease refrigerators, freezers, ultra-cold units, and generators to them, all monitored by Callan JMB's proprietary Sentry monitoring system. The lease program includes computer equipment, compliant inventory management, and mobile clinic kits that keep vaccines at required temperatures throughout transit and include everything needed for successful immunizations. While there are grants available for vaccine management plans through Public Health Emergency Preparedness (PHEP) programs, many do not cover the purchase of equipment. Drawing on extensive emergency preparedness and response logistics expertise, Callan JMB's vaccine and compliance specialists offer this lease program across all public health initiatives--from immunization programs and rural medical response units to pandemic preparedness plans. The program delivers a state-of-the-art, full-service management system emphasizing quality, responsibility, and accountability. Since 2009, Callan JMB has pioneered the development of fully compliant vaccine management centers for secure storage and efficient distribution. The COVID-19 pandemic proved to be the ultimate test for these facilities, with the Company's centers in Texas, Oregon, and Illinois demonstrating exceptional effectiveness. From April 2020 through January 2024, Callan JMB successfully managed the distribution of 2.27 million COVID-19 vaccine doses, 32.2 million testing supplies, and 113,401 COVID-19 therapeutics for the Texas Department of State Health Services.お知らせ • Feb 10Callan JMB Inc. Appoints Three Directors to Its Board of DirectorsOn February 4, 2025, Callan JMB Inc. appointed three directors (the New Directors") to its board of directors (the Board of Directors"). The New Directors are Liberty Duke, Mark Meller and Gerald Dial. Each of the New Directors has been appointed a member of the Company's Audit, Compensation and Nominating and Corporate Governance committees. Mr. Meller has been appointed Chair of the Audit Committee, Ms. Duke has been appointed Chair of the Compensation Committee and Mr. Dial has been appointed Chair of the Nominating and Corporate Governance Committee.株主還元CJMBUS LogisticsUS 市場7D68.5%-0.3%1.0%1Y-53.9%26.0%18.4%株主還元を見る業界別リターン: CJMB過去 1 年間で26 % の収益を上げたUS Logistics業界を下回りました。リターン対市場: CJMBは、過去 1 年間で18.4 % のリターンを上げたUS市場を下回りました。価格変動Is CJMB's price volatile compared to industry and market?CJMB volatilityCJMB Average Weekly Movement27.0%Logistics Industry Average Movement7.5%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: CJMBの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CJMBの 週次ボラティリティ は過去 1 年間で43%から27%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200619Wayne Williamscallanjmb.comCallan JMB Inc.は、子会社であるColdchain Technology Services, LLCを通じて、米国のライフサイエンス業界向けに温度管理物流ソリューションを提供しています。 同社は、個別化医療、細胞療法、幹細胞、細胞株、ワクチン、診断用試料、精液、卵子、胚、臍帯血、臓器、バイオ医薬品、感染性物質、その他の商品など、ライフサイエンス業界における冷凍輸送に活用される物流ソリューションおよびサービスを提供しています。 また、同社は、施設の管理、医療機器や物資の備蓄、州や地方自治体の緊急事態への対応を含む緊急事態対応サービス、特殊な温度管理包装、技術サービス、および高度なモニタリング・セントリー技術も提供しています。Callan JMB Inc.は、米国の医薬品製造およびサプライチェーンのレジリエンス（回復力）を向上させるため、アラバマ州立大学と戦略的パートナーシップを結んでいます。 同社は2006年に設立され、テキサス州スプリング・ブランチに本社を置いている。もっと見るCallan JMB Inc. 基礎のまとめCallan JMB の収益と売上を時価総額と比較するとどうか。CJMB 基礎統計学時価総額US$10.84m収益（TTM）-US$9.94m売上高(TTM)US$5.38m2.3xP/Sレシオ-1.2xPER（株価収益率CJMB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CJMB 損益計算書（TTM）収益US$5.38m売上原価US$3.46m売上総利益US$1.92mその他の費用US$11.86m収益-US$9.94m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.76グロス・マージン35.61%純利益率-184.78%有利子負債／自己資本比率0%CJMB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/12 06:11終値2026/08/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Callan JMB Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 116% per year over the past 5 years. Market cap is less than US$10m (US$4.86m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
お知らせ • Jul 04Callan Jmb Inc Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementOn June 29, 2026, Callan JMB Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer satisfies the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 28, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period, although Nasdaq may, in its discretion, require the Company to maintain a closing bid price of at least $1.00 per share for a period in excess of ten consecutive business days (generally no more than 20 consecutive business days) before determining that the Company has regained compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by December 28, 2026, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the applicable compliance period(s), Nasdaq will provide notice that the Company’s common stock will be subject to delisting, at which time the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, which may include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or will otherwise maintain compliance with the other listing requirements of The Nasdaq Capital Market.
お知らせ • Jun 12Callan Jmb Inc. Announces Resignation of Eric Kash from Executive Vice President and Board Member Roles, Effective June 5, 2026Callan JMB Inc. announced that on June 5, 2026, Eric Kash resigned from his position as Executive Vice President of Callan JMB Inc., and from his position as a member of the Board of Directors of the Company, including any committee positions, effective as of June 5, 2026. Mr. Kash's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
お知らせ • May 28Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • May 18First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.32 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.32 loss in 1Q 2025). Revenue: US$1.11m (down 24% from 1Q 2025). Net loss: US$3.22m (loss widened 159% from 1Q 2025).
お知らせ • Apr 12Callan JMB Inc. Receives Nasdaq Notice of Non-Compliance with Stockholders' Equity RequirementOn April 7, 2026 Callan JMB Inc. (the Company) received a deficiency letter (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market (the Stockholders' Equity Requirement). In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 22, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement. Subsequent to the receipt of the Notice, and prior to that deadline, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement to Nasdaq. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq may, in its discretion, grant the Company up to 180 calendar days from the date of the Notice, or until October 4, 2026, to evidence compliance. Neither the Notice nor the Company's non-compliance have an immediate effect on the listing or trading of the Company's common stock, which will continue to trade under the symbol CJMB. However, these can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance.
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 116% per year over the past 5 years. Market cap is less than US$10m (US$4.86m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
お知らせ • Jul 04Callan Jmb Inc Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementOn June 29, 2026, Callan JMB Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer satisfies the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 28, 2026, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period, although Nasdaq may, in its discretion, require the Company to maintain a closing bid price of at least $1.00 per share for a period in excess of ten consecutive business days (generally no more than 20 consecutive business days) before determining that the Company has regained compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by December 28, 2026, the Company may be eligible for an additional compliance period of 180 calendar days. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the applicable compliance period(s), Nasdaq will provide notice that the Company’s common stock will be subject to delisting, at which time the Company may appeal Nasdaq’s determination to a Nasdaq Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, which may include effecting a reverse stock split. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or will otherwise maintain compliance with the other listing requirements of The Nasdaq Capital Market.
お知らせ • Jun 12Callan Jmb Inc. Announces Resignation of Eric Kash from Executive Vice President and Board Member Roles, Effective June 5, 2026Callan JMB Inc. announced that on June 5, 2026, Eric Kash resigned from his position as Executive Vice President of Callan JMB Inc., and from his position as a member of the Board of Directors of the Company, including any committee positions, effective as of June 5, 2026. Mr. Kash's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
お知らせ • May 28Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Callan JMB Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • May 18First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.32 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.32 loss in 1Q 2025). Revenue: US$1.11m (down 24% from 1Q 2025). Net loss: US$3.22m (loss widened 159% from 1Q 2025).
お知らせ • Apr 12Callan JMB Inc. Receives Nasdaq Notice of Non-Compliance with Stockholders' Equity RequirementOn April 7, 2026 Callan JMB Inc. (the Company) received a deficiency letter (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market (the Stockholders' Equity Requirement). In accordance with Nasdaq Listing Rules, the Company has been provided an initial period of 45 calendar days, or until May 22, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement. Subsequent to the receipt of the Notice, and prior to that deadline, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement to Nasdaq. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq may, in its discretion, grant the Company up to 180 calendar days from the date of the Notice, or until October 4, 2026, to evidence compliance. Neither the Notice nor the Company's non-compliance have an immediate effect on the listing or trading of the Company's common stock, which will continue to trade under the symbol CJMB. However, these can be no assurance that the Company's plan will be accepted or that if it is, the Company will be able to regain compliance.
New Risk • Apr 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (82% average weekly change). Revenue has declined by 13% over the past year. Market cap is less than US$10m (US$7.37m market cap). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Reported Earnings • Apr 04Full year 2025 earnings released: US$1.82 loss per share (vs US$0.87 loss in FY 2024)Full year 2025 results: US$1.82 loss per share (further deteriorated from US$0.87 loss in FY 2024). Revenue: US$5.72m (down 13% from FY 2024). Net loss: US$7.97m (loss widened 247% from FY 2024).
お知らせ • Mar 11Callan Jmb Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’S Ind Clinical Trials for Lodonal™ in the Treatment of Long CovidCallan JMB Inc. announced that it has agreed with Biostax Corp. d/b/a Attune Biotech Inc. to support its investigational new drug clinical trials for the treatment of Post-Acute Sequelae of SARS-CoV-2 infection (“PASC”), commonly known as Long COVID. The Company previously announced in January 2026, that it had signed a strategic teaming agreement with Attune, whereby Callan JMB serves as independent third-party overseer of Attune's manufacturing, quality assurance and control, and deployment operations. Under this agreement, Callan JMB will provide the following services and oversight for IND 181314 for JKB-122 (lodonal™), including Contract Manufacturing Organization (CMO) qualification and validation, comprehensive batch record review, supply chain verification and integrity confirmation, surge manufacturing capacity assessment, and distribution pathway validation. Attune has received notification that the U.S. Food and Drug Administration (FDA) has received and assigned Investigational New Drug (IND) application number 181314 for JKB-122 (lodonal™) for treatment of Long COVID, which remains a condition for which no FDA-approved therapies are currently indicated. Patients of Long COVID are currently underserved, with approximately 20 million Americans estimated to be living with Long COVID or persistent post-COVID symptoms. In addition, the U.S. Department of Health and Human Services (HHS) has issued formal guidance titled “Long COVID as a Disability Under the ADA, Section 504, and Section 1557” (last reviewed July 2025), confirming that Long COVID may qualify as a disability under federal civil rights statutes where symptoms substantially limit major life activities. lodonal™ (JKB-122) is a first-in-class TLR4 antagonist for immune restoration, currently in development across five parallel clinical programs including Long COVID, HIV immune non-responders, autoimmune hepatitis, metabolic liver diseases (MASLD/MASH), and chronic immune pain. Under IND 181314, Attune intends to initiate a randomized, double-blind, placebo-controlled, multi-center Phase 2b/3 clinical trial evaluating the safety, tolerability, and efficacy of JKB-122 (lodonal™) in adults diagnosed with PASC or Long COVID. The product remains investigational and has not been approved by the U.S. Food and Drug Administration. JKB-122 is protected by issued intellectual property extending through 2041.
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 81% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (81% average weekly change). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$5.18m market cap).
お知らせ • Dec 07Callan JMB Inc. Appoints Christopher Shields as Interim Chief Financial Officer, Effective December 1, 2025Callan JMB Inc. appointed Christopher Shields, the Company’s Senior Vice President (Governmental Affairs), to serve as Interim Chief Financial Officer until a permanent Chief Financial Officer is appointed, effective December 1, 2025. Mr. Shields, age 57, has served as the Company’s Senior Vice President (Governmental Affairs), since April 15, 2025, pursuant to the employment agreement, dated March 15, 2025. Prior to joining the Company, Mr. Shields served as Assistant Commissioner (Bureau of Preparedness and Response) with Chicago Department of Public Health, City of Chicago, from February 2011 to March 2025, where he led City of Chicago’s efforts to prepare for and respond to the health consequences of disasters including severe weather, special events, infectious diseases, chemical/biological/radiological releases. Additionally, Mr. Shields has more than three decades of experience managing operations and logistics components of various stages and branches of public health emergency preparedness and response, among others. Mr. Shields received a B.S., in Community Health Administration in 1990 from Northern Illinois University, DeKalb, Illinois, and also completed the Critical Infrastructure Protection Certificate Program at the Texas A&M Engineering Extension Service (TEEX) between 2016 to 2017. Mr. Shields currently serves on Northern Illinois University’s College of Health and Human Sciences Advisory Board.
New Risk • Dec 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Dec 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Revenue has declined by 14% over the past year. Market cap is less than US$10m (US$9.75m market cap).
お知らせ • Dec 01Callan JMB Inc., Annual General Meeting, Dec 29, 2025Callan JMB Inc., Annual General Meeting, Dec 29, 2025.
Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.61 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.61 loss per share (further deteriorated from US$0.27 loss in 3Q 2024). Revenue: US$1.45m (flat on 3Q 2024). Net loss: US$2.73m (loss widened 239% from 3Q 2024).
お知らせ • Nov 11Callan JMB Inc. Expands Logistics Platform into Food Sampling Sector, Advancing Multi-Variant Growth StrategyCallan JMB Inc. announced the expansion of its reclamation operations into the food sampling industry. This move is part of Callan JMB's multi-variant strategic growth initiative designed to extend its proven compliance-driven model into adjacent, high-growth markets. Building on a long history of excellence in pharmaceutical and regulated material logistics, Callan JMB is applying its expertise in product integrity, recall readiness, and traceability to support the specialized needs of food brands and distributors managing large-scale sampling programs. While most food sampling programs focus on reach and trial, few have standardized sustainable packaging or waste-reduction practices -- creating an accountability gap. As brands face increasing pressure to cut waste and measure impact, the sampling channel presents a clear opportunity for logistics partners that deliver sustainability, compliance, and traceability. The expansion was made possible through Callan JMB's relationship with Keychain, an AI-powered platform for the consumer packaged goods (CPG) industry. Supporting over $1 billion in monthly manufacturing projects, Keychain's platform connects 30,000 manufacturers with 20,000 brands and retailers, helping them bring new products to market faster, more responsibly, and with greater precision. While specific forecasts for food sampling services are limited, the broader food logistics market--valued at over $120 billion globally and growing at a rate of 6-10% annually-- offers a strong platform for expansion. Callan JMB's entry into this fast-emerging segment supports brands responding to the growing demand for sustainable, compliant sampling and distribution. With the U.S. specialty food sector projected to reach $130 billion by 2032 (Data Bridge Market Research, 2024), this expansion reinforces Callan JMB's commitment to diversification, sustainability, and cross-sector resilience.
お知らせ • Oct 14Callan Jmb Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature MonitoringCallan JMB INC. announced that it has upgraded its proprietary Sentry Monitoring System technology with version 4.0 for temperature-sensitive storage to significantly increase flexibility and accessibility for its customers. The Sentry Monitoring System is a platform that allows remote monitoring of refrigerators, freezers, and clean room temperatures for high-value pharmaceutical products in pharmacies, hospitals, and emergency preparedness facilities. The upgraded version, Sentry 4.0, provides the user with the same 24/7/365 active monitoring by Callan JMB staff, alarm notifications, and compliant reporting data that are currently available with the Sentry 3 system, but with improved accessibility for users on the go. Sentry 4.0 allows users to access a consistent interface across all systems and devices - PC or Mac, an iPhone or Android, or any tablet. This flexibility enables the customer to address environmental anomalies in their pharmaceutical storage units from any available device, without having to download additional programs. With Sentry 4.0, Callan JMB has raised the bar for secure, reliable, and easy-to-use temperature monitoring that is critical to the medical and pharmaceutical industries. The upgraded system is now available to new and existing customers.
Reported Earnings • Aug 15Second quarter 2025 earnings released: US$0.31 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.31 loss per share (further deteriorated from US$0.015 loss in 2Q 2024). Revenue: US$1.67m (down 16% from 2Q 2024). Net loss: US$1.40m (loss widened US$1.28m from 2Q 2024).
お知らせ • Jul 26Callan JMB Inc. announced that it expects to receive $25 million in fundingCallan JMB Inc. announced it has entered into a Purchase Agreement with a certain investor (ELOC agreement) whereby the Company has the right, but not the obligation, to sell to the Investor, up to an aggregate of $25,000,000 of shares (the “ ELOC Shares ”) of the Company’s common stock, par value $0.001 per share, subject to the terms and conditions on July 24, 2025. The term of the Purchase Agreement is through the first day of the month immediately following the eighteen (18) month anniversary of the Commencement Date or the date on which the Investor has purchased ELOC Shares pursuant to the Purchase Agreement for an aggregate purchase price of the Investment Amount. The Company has also agreed to issue to the Investor 15,000 shares of Common Stock (the “ Commitment Shares ”), to be issued to the Investor upon the effectiveness of the registration statement registering the resale of the ELOC Shares and the Commitment Shares. The issuance of the shares of ELOC Shares to the Investor is being made pursuant to exemptions from the registration requirement of the Securities Act of 1933, as amended (the “ Securities Act ”) provided by Section 4(a)(2) of the Securities Act.
分析記事 • Jul 17Companies Like Callan JMB (NASDAQ:CJMB) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • May 16First quarter 2025 earnings released: US$0.32 loss per share (vs US$0.032 loss in 1Q 2024)First quarter 2025 results: US$0.32 loss per share (further deteriorated from US$0.032 loss in 1Q 2024). Revenue: US$1.45m (down 19% from 1Q 2024). Net loss: US$1.24m (loss widened US$1.16m from 1Q 2024).
お知らせ • Apr 25Callan JMB Inc. Appoints Christopher Shields, as Senior Vice President of Emergency Preparedness & Response/Government AffairsCallan JMB INC. announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Mr. Shields is an industry veteran with decades of experience managing complex public safety responses to a diverse array of crises both domestically and internationally. Most recently, Mr. Shields served for over 14 years as Assistant Commissioner at the Chicago Department of Public Health, where he oversaw operations and logistics for the city’s Emergency Preparedness and Bioterrorism program. His responsibilities included managing day-to-day operations of the Tier 1 Medical Pharmacy, overseeing advanced vaccine inventory and storage systems, and leading critical functions such as the Continuity of Operations group, Emergency Operations Planning team, and Tactical Communications platform. Mr. Shields has held various leadership positions responsible for humanitarian aid/disaster relief (HADR) and emergency responses to health impacts including September 11, 2001, Hurricane Katrina 2005, H1N1 Pandemic 2009-2010, NATO 2012, Ebola 2014-2016, Hurricane Maria, SARSCoV-2 Pandemic 2020-2023, Operation Allies welcome, Monkey Pox MPV outbreak 2022, humanitarian migration response from South America (2022 - ongoing), Ebola (Sudan virus) 2022-2023, Measles 2024, the Democratic National Convention (DNC) 2024 and the Rwanda Marburg operation/ORD 2024.
Recent Insider Transactions • Apr 04Chief Medical Officer recently bought US$113k worth of stockOn the 27th of March, David Croyle bought around 25k shares on-market at roughly US$4.50 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$253k. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months.
Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive VP & Director Eric Kash is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 30Full year 2024 earnings released: US$0.87 loss per share (vs US$0.44 profit in FY 2023)Full year 2024 results: US$0.87 loss per share (down from US$0.44 profit in FY 2023). Revenue: US$6.56m (down 50% from FY 2023). Net loss: US$2.29m (down 205% from profit in FY 2023).
お知らせ • Feb 28Callan Jmb Inc. Unveils Innovative Immunization Management Infrastructure Lease Program for Government Agencies and Private OrganizationsCallan JMB INC. announced a new comprehensive lease program for vaccine management that will enable government agencies and private organizations to provide crucial immunizations without the economic burden of purchasing the necessary equipment outright. Under this program, Callan JMB can not only assist agencies in developing their plans, but can lease refrigerators, freezers, ultra-cold units, and generators to them, all monitored by Callan JMB's proprietary Sentry monitoring system. The lease program includes computer equipment, compliant inventory management, and mobile clinic kits that keep vaccines at required temperatures throughout transit and include everything needed for successful immunizations. While there are grants available for vaccine management plans through Public Health Emergency Preparedness (PHEP) programs, many do not cover the purchase of equipment. Drawing on extensive emergency preparedness and response logistics expertise, Callan JMB's vaccine and compliance specialists offer this lease program across all public health initiatives--from immunization programs and rural medical response units to pandemic preparedness plans. The program delivers a state-of-the-art, full-service management system emphasizing quality, responsibility, and accountability. Since 2009, Callan JMB has pioneered the development of fully compliant vaccine management centers for secure storage and efficient distribution. The COVID-19 pandemic proved to be the ultimate test for these facilities, with the Company's centers in Texas, Oregon, and Illinois demonstrating exceptional effectiveness. From April 2020 through January 2024, Callan JMB successfully managed the distribution of 2.27 million COVID-19 vaccine doses, 32.2 million testing supplies, and 113,401 COVID-19 therapeutics for the Texas Department of State Health Services.
お知らせ • Feb 10Callan JMB Inc. Appoints Three Directors to Its Board of DirectorsOn February 4, 2025, Callan JMB Inc. appointed three directors (the New Directors") to its board of directors (the Board of Directors"). The New Directors are Liberty Duke, Mark Meller and Gerald Dial. Each of the New Directors has been appointed a member of the Company's Audit, Compensation and Nominating and Corporate Governance committees. Mr. Meller has been appointed Chair of the Audit Committee, Ms. Duke has been appointed Chair of the Compensation Committee and Mr. Dial has been appointed Chair of the Nominating and Corporate Governance Committee.
